Every 424B that ImageneBio, Inc. (IMA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMA filings page.
ImageneBio, Inc. provides an updated prospectus supplement for the resale of up to 2,508,337 shares of common stock under its Form S-1 registration statement (No. 333-290108). The shares may be offered and sold from time to time by identified selling stockholders.
The supplement incorporates information from ImageneBio’s Quarterly Report on Form 10-Q filed on August 5, 2026, which is attached in relevant part. The company’s common stock trades on the Nasdaq Capital Market under the symbol IMA, and the last reported sale price was $5.71 per share on August 4, 2026.
The document emphasizes that investing in these securities involves a high degree of risk and directs readers to the “Risk Factors” section in the base prospectus and any amendments or supplements.
ImageneBio, Inc. filed a prospectus supplement covering the proposed resale, from time to time, of 2,508,337 shares of common stock by selling stockholders under an existing Form S-1. The common stock trades on the Nasdaq Capital Market under the symbol IMA; the last reported sale price was $5.97 per share on July 22, 2026.
The company also appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer and principal accounting officer effective July 20, 2026. Her employment terms include a $450,000 annual base salary, eligibility for an annual discretionary bonus targeted at 40% of base salary, an initial option to purchase 95,000 shares, and 65,000 restricted stock units, each vesting over four years. She will participate as a C-suite officer in the company’s Severance and Change in Control Plan, which can provide up to 12 months of salary, a 100% target bonus payout, continued health benefits for up to 12 months, and full equity acceleration upon a qualifying covered termination during a change in control period.
Effective July 24, 2026, Chief Medical Officer Benjamin Porter-Brown will transition from a full-time role to a consulting position, continuing to advise on clinical development and strategy.
ImageneBio, Inc. filed a prospectus supplement to its Form S-1 registering the resale or other disposition of 2,508,337 shares of Common Stock. The supplement incorporates portions of a Form 8-K noting that Senior VP of Finance and Operations Robert Lally gave notice of resignation, effective July 22, 2026. The supplement states the last reported sales price was $6.02 per share on June 26, 2026 and that the selling stockholders, identified in the prospectus, propose to offer those shares from time to time.
ImageneBio, Inc. filed a prospectus supplement registering 2,508,337 shares of Common Stock for resale by the selling stockholders. The supplement attaches portions of a Form 8-K reporting that stockholders approved an amendment to the 2025 Equity Incentive Plan increasing the plan reserve by 850,000 shares. The filing states 11,279,130 shares outstanding as of April 28, 2026 and notes a last reported sales price of $5.45 per share on June 16, 2026. The Amended Plan also describes an automatic annual increase equal to 5% of specified share counts beginning January 1, 2027.
ImageneBio, Inc. files a prospectus supplement to register 2,508,337 shares of Common Stock for offer and resale by identified selling stockholders. The supplement updates the April 2, 2026 prospectus with selected Form 10-Q information and notes a last reported sale price of $6.08 per share on May 6, 2026.
The registration relates to resale or other dispositions "from time to time by the selling stockholders" under Registration No. 333-290108; the supplement is dated May 7, 2026 and references the Prospectus dated April 2, 2026.
ImageneBio, Inc. registers 2,508,337 shares of Common Stock for resale by the selling stockholders identified in the prospectus supplement. The resale prospectus supplement updates the Form S-1 registration (No. 333-290108) and incorporates specified portions of the company’s Form 10-Q filed May 7, 2026.
The Common Stock trades on the Nasdaq Capital Market under the symbol IMA; the last reported sales price on May 6, 2026 was $6.08 per share. The prospectus supplement states proceeds from resales will be received by the selling stockholders, not the issuer.
ImageneBio, Inc. files a prospectus supplement registering 2,508,337 shares of Common Stock for resale by identified selling stockholders. The supplement incorporates a Form 8-K disclosing a related private placement of pre-funded warrants to purchase up to 5,770,335 Warrant Shares at $5.199 per Warrant Share for gross proceeds of approximately $30 million, with the pre-funded warrants exercisable at $0.001 per share and subject to beneficial ownership limits (including 19.99%). The registration covers resale by selling holders; proceeds from those resales will go to the selling holders, not the company.
ImageneBio, Inc. files a prospectus supplement registering 2,508,337 shares of common stock for resale by selling stockholders. The supplement incorporates parts of a Form 8-K dated February 17, 2026 and updates the Prospectus dated September 15, 2025.
The supplement states the last reported sales price was $6.85 per share on February 13, 2026. The Form 8-K disclosed that Steven Hui Wang resigned from the Board effective February 12, 2026, and the Company says his resignation was not due to any disagreement with the Company on operations, policies, practices or strategy.
ImageneBio, Inc. has filed a prospectus supplement covering the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement incorporates information from a recent current report that notes Chief Medical Officer Yufang Lu, M.D., Ph.D. has notified the company of her resignation, effective December 31, 2025. The company states that her resignation is not due to any disagreement related to operations, policies or practices. ImageneBio is conducting a search for her replacement, and Dr. Lu is expected to provide transition advisory services after her resignation date. The company’s common stock trades on the Nasdaq Capital Market under the symbol IMA, and last traded at $6.24 per share on December 17, 2025.
ImageneBio, Inc. filed a prospectus supplement covering the proposed offer and resale, from time to time, by selling stockholders of 2,508,337 shares of common stock.
The supplement updates the base prospectus by attaching the company’s Quarterly Report on Form 10-Q filed on November 12, 2025. ImageneBio’s common stock trades on the Nasdaq Capital Market under the ticker IMA; the last reported sales price was $8.61 per share on November 11, 2025. The filing reiterates that investing in the securities involves a high degree of risk, directing readers to the Risk Factors in the prospectus.
ImageneBio filed a Rule 424(b)(3) prospectus supplement to its Form S-1, relating to the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement updates the prospectus with information from a Current Report on Form 8-K. The company’s common stock trades on Nasdaq as “IMA,” and the last reported sales price was $8.24 per share on November 4, 2025.
The attached 8-K reports the Board increased its authorized size from six to seven directors and appointed Joseph P. Slattery to the Board effective November 1, 2025, and as Chair of the Audit Committee effective November 18, 2025. The company entered into its standard indemnification agreement with Mr. Slattery.
ImageneBio, Inc. filed a prospectus supplement covering the proposed offer and resale of 2,508,337 shares of common stock by selling stockholders. The supplement updates the base prospectus with recent disclosures and attaches three Current Reports on Form 8‑K.
- On October 10, 2025, CFO and principal financial officer Jotin Marango, M.D., Ph.D., resigned effective October 20, 2025; the resignation was not due to any disagreement.
- On October 21, 2025, the board appointed CEO Kristin Yarema, Ph.D., as interim principal financial officer, effective immediately.
- On October 23, 2025, the company elected not to automatically renew a transition services agreement with Miragene Inc. and extended a subset of services for six months; total fees for the extension services are $200,000.
The company’s common stock trades on Nasdaq as “IMA.” On October 29, 2025, the last reported sale price was $8.79 per share.